AUPH — Aurinia Pharmaceuticals Inc.

Summary of Aurinia Pharmaceuticals Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 2025 Total Revenue: $77.1 million, a 29% increase from $59.9 million in Q4 2024.
• Net Product Sales of LUPKYNIS: $74.2 million, up 29% from $57.6 million in the same quarter last year.
• Net Income: $210.8 million, a significant increase of 14,957% from $1.4 million in Q4 2024, largely due to a $175.1 million income tax benefit from deferred tax assets.
• Diluted Earnings Per Share (EPS): $1.53, up 15,200% from $0.01 in Q4 2024.
• Cash Flow from Operating Activities: $45.7 million, a 52% increase from $30.1 million in Q4 2024.
• Full Year 2025 Total Revenue: $283.1 million, up 20% from $235.1 million in 2024.
• Full Year Net Income: $287.2 million, up 4,852% from $5.8 million in 2024.
• Cash Position: $398 million as of December 31, 2025, compared to $358.5 million at the end of 2024.

2. Strategic Updates and Business Highlights

• LUPKYNIS Sales Growth: Continued strong performance with a year-over-year growth rate of 25%. The company aims to leverage clinical data and updated treatment guidelines to enhance market penetration.
• Clinical Development of Aritinercept: Initiated a clinical study in one autoimmune disease, with plans for another study in the first half of 2026. Aritinercept is positioned as a dual BAFF April inhibitor with potential across various autoimmune conditions.
• Market Positioning: Aurinia is focusing on changing the treatment paradigm for lupus nephritis through earlier diagnosis and aggressive treatment, supported by recent ACR and ULAR guidelines.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected total revenue of $315 million to $325 million, representing an 11% to 15% increase compared to 2025.
• Net Product Sales Guidance: Anticipated net product sales of $305 million to $315 million, up 12% to 16% from the previous year.

4. Bad News, Challenges, or Points of Concern

• Competitive Pressures: The recent approval of Gazyva for lupus nephritis could pose a challenge, although management noted no immediate impact on LUPKYNIS sales. They acknowledged the need to remain vigilant about competition and market dynamics.
• Clinical Study Challenges: The termination of the pediatric study due to recruitment difficulties raises concerns about the company's ability to meet regulatory commitments in this area.
• Market Penetration in Global Markets: Aurinia does not expect significant growth in international markets compared to the U.S. due to varying pricing and reimbursement landscapes.

5. Notable Q&A Insights

• Commercial Outlook for 2026: Management indicated that their guidance is conservative, based on historical performance and market conditions, rather than the strong Q4 run rate.
• Impact of New Guidelines: The emphasis on earlier diagnosis and treatment in the new guidelines could enhance LUPKYNIS adoption, although current adherence to these practices remains inconsistent.
• Combination Therapies: There is interest in exploring the combination of B-cell and T-cell therapies for lupus nephritis, which could enhance treatment efficacy.
• Future Updates on Aritinercept: More information on the aritinercept program is expected in the second quarter of 2026, but specific details on study design and indications remain undisclosed for competitive reasons.

Overall, Aurinia Pharmaceuticals demonstrated strong financial performance in Q4 2025, with promising growth in LUPKYNIS sales and ongoing clinical development efforts. However, competitive pressures and challenges in clinical studies present potential risks to future growth.